The goal of the MRIE is Simple
Better prevention, diagnosis, and treatment strategies for melanoma patients at the Sidney Kimmel Cancer Center and far beyond.
Our clinical trials provide patients who may have limited standard of care (FDA-approved therapies) options an opportunity to participate in new, investigative treatments.
MRIE Grants & Awards
Made possible through the generosity of benefactors, MRIE grants provide funding to worthy SKCC investigators and their collaborators to conduct innovative melanoma research.
Pilot Awards provide funding which supports researchers to develop innovative solutions that will prevent, delay, eradicate and/or provide education about uveal and cutaneous melanoma.
Team Award Program
Team Awards provide funding to support collaborative teams in exploring new frontiers in uveal and cutaneous melanoma research.
Melanoma Research Institute of Excellence (MRIE) Scientific Retreat
Melanoma investigators and others from Jefferson and affiliated institutions are invited to attend the Melanoma Research Institute of Excellence (MRIE) Scientific Retreat. Recipients of MRIE grants will present reports on their research projects, and attendees will discuss future collaborative opportunities and exchange ideas and strategies. Following the conference, an informal reception will start at 5 p.m.
When: Friday, Feb. 16, 1-5 p.m.
Where: Hamilton Building, 1001 Locust St. – Room 505
Shingo Sato, the MRIE’s Associate Program Manager, is partaking in an Educational Fellowship titled “Artificial Intelligence Applications for Cancer Diagnosis and Treatment in Melanoma”. Shingo is spending the first quarter of 2024 in Osaka, Japan receiving hands-on experiential learning from the AI team at Osaka Metropolitan University, where they are developing applications and algorithms for use in medical imaging. The purpose of this fellowship program is to yield a comprehensive understanding of AI core principles with an eye on the development and utilization of AI as a diagnostic and treatment tool relating to metastatic uveal melanoma. Shingo will bring this knowledge to SKCC/TJU for further research and ultimately to apply in practical, real-world medical imaging scenarios.